Sucampo Pharmaceuticals Inc (NASDAQ:SCMP)

14.97
Delayed Data
As of Mar 03
 +1.37 / +10.07%
Today’s Change
5.80
Today|||52-Week Range
16.54
+4.83%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$603.1M

Company Description

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies. Prostones are naturally occurring fatty acid metabolites with unique physiological activities and can be targeted for the treatment of unmet or underserved medical needs. It is focused on developing and commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of its drug technologies. The company was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.

Contact Information

Sucampo Pharmaceuticals, Inc.
4520 East West Highway
Bethesda Maryland 20814-3392
P:(301) 961-3400
Investor Relations:
(240) 223-3718

Employees

Shareholders

Individual stakeholders71.62%
Other institutional16.12%
Mutual fund holders13.48%

Top Executives

Peter S. GreenleafChief Executive Officer & Director
Andrew P. SmithChief Financial Officer
Taryn R. JoswickVice President-Clinical Development
Peter Alec KienerChief Scientific Officer
Thomas J. KnappSecretary, Chief Legal Officer & Executive VP

To view my watchlist

Not a member yet?

Sign up now for a free account